Liminatus Pharma, Inc.
10-K
March 31, 2026
Key Highlights
- Developing IBA101, a novel antibody cancer treatment designed to spare healthy c...
- Successfully completed pre-clinical animal safety studies.
- Potential expansion into chronic inflammation and weight loss markets.
Read Analysis
🤖 AI Generated